Blog
RSS FeedPosted by Michael Wonder on 18 Jul 2019
Two cancer immunotherapy makers face different situations in reimbursement talks
18 July 2019 - MSD returns to renegotiation table; BMS suffers from partner’s silence. ...
Posted by Michael Wonder on 18 Jul 2019
LifeMax receives rare paediatric disease designation for LM-030 for the treatment of Netherton syndrome
18 July 2019 - LifeMax Laboratories today announced that the FDA granted rare paediatric disease designation to LM-030, an investigational therapy ...
Posted by Michael Wonder on 17 Jul 2019
On drug prices, Trump must resist left-wing approaches that would lead to disaster
17 July 2019 - In Friday's column, I explained why President Donald Trump and the Republicans are on their way ...
Posted by Michael Wonder on 17 Jul 2019
Car shopping, handbags and wealthy uncles: the quest to explain high drug prices
17 July 2019 - High drug prices are a hot topic in politics right now. President Trump has made lowering ...
Posted by Michael Wonder on 17 Jul 2019
Durect announces that the FDA agreed to file the full response to the Posimir complete response letter as a complete Class 2 resubmission
17 July 2019 - User fee goal date is 27 December 2019. ...
Posted by Michael Wonder on 17 Jul 2019
U.S. FDA accepts Allergan's new drug application for bimatoprost sustained release in patients with open-angle glaucoma or ocular hypertension
17 July 2019 - Filing included data from the Phase 3 ARTEMIS studies, which demonstrated that the majority of patients remained ...
Posted by Michael Wonder on 17 Jul 2019
FDA approves Merck’s Recarbrio (imipenem, cilastatin, and relebactam) for the treatment of adults with complicated urinary tract and complicated intra-abdominal bacterial infections where limited or no alternative treatment options are available
17 July 2019 - Merck today announced that the U.S. FDA has approved Recarbrio (imipenem, cilastatin, and relebactam) for injection, 1.25 ...
Posted by Michael Wonder on 17 Jul 2019
Kamala Harris introduces plan to lower prescription drug prices
16 July 2019 - Senator Kamala Harris unveiled a plan Tuesday to lower prescription drug prices if she's elected president. ...
Posted by Michael Wonder on 17 Jul 2019
Breast cancer patients to have further NICE approved drug combination option on Cancer Drugs Fund
17 July 2019 - Another potentially life-extending drug combination for some people with advanced breast cancer will now be available on ...
Posted by Michael Wonder on 17 Jul 2019
Drug Utilisation Sub-Committee outcome statement
17 July 2019 - The outcome statement from the June 2019 Drug Utilisation Sub-Committee meeting is now available. ...
Posted by Michael Wonder on 17 Jul 2019
Knight Therapeutics announces Health Canada has approved Nerlynx for early-stage breast cancer
16 July 2019 - Knight Therapeutics announced today that Health Canada has approved Nerlynx (neratinib) for the extended adjuvant treatment of ...
Posted by Michael Wonder on 16 Jul 2019
How pharma, under attack from all sides, keeps winning in Washington
16 July 2019 - It does not seem to matter how angrily President Trump tweets, how pointedly House Speaker Nancy ...
Posted by Michael Wonder on 16 Jul 2019
Price increases of protected-class drugs in Medicare Part D, relative to inflation, 2012-2017
16 July 2019 - In recent years, the Centers for Medicare & Medicaid Services has considered allowing greater flexibility in ...
Posted by Michael Wonder on 16 Jul 2019
National regulator denied offer to give Canadian physicians training on abortion pill
16 July 2019 - The group representing Canada’s family doctors turned down an offer from a national abortion group to ...
Posted by Michael Wonder on 16 Jul 2019
Ask whether a drug works before worrying about what it costs
16 July 2019 - Last week was supposed to be a turning point for drug price transparency. ...